Saturday 31 October 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
62.55
1.16
+1.89%
Follow BMY
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
22.27 | 100.51 | 17.16 | 29.05 | 0.00 | 19.79 | 24.25 | 13.60 | 0.00 | 15.59 |
Piotroski F-Score |
6 | 6 | 9 | 3 | 5 | 8 | 6 | 7 | 4 | 8 |
Altman Z-Score |
6.10 | 5.40 | 5.25 | 1.64 | 1.57 | 2.23 | 2.57 | 2.28 | 1.43 | 2.14 |
P/S ratio |
5.11 | 4.85 | 3.76 | 4.19 | 3.29 | 2.99 | 3.33 | 2.43 | 2.37 | 2.28 |
P/FCF ratio |
53.90 | 23.90 | 13.88 | 14.84 | 10.53 | 9.09 | 12.88 | 8.63 | 8.22 | 8.54 |
Altman Z″-Score (non-manufacturers) |
6.36 | 5.66 | 6.36 | 2.37 | 1.30 | 2.41 | 2.26 | 2.71 | 0.57 | 2.01 |
Beneish M-Score |
(2.03) | (3.05) | (2.83) | (1.97) | (3.30) | (2.84) | (2.76) | (2.70) | (3.75) | (2.69) |
P/Operating CF |
68.84 | 90.29 | 23.88 | 50.18 | 41.75 | 34.13 | 46.56 | 25.67 | 25.83 | 55.58 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 63 |
P/B ratio |
6.08 | 8.51 | 6.01 | 2.12 | 3.70 | 3.85 | 4.95 | 3.70 | 7.00 | 5.93 |
Price to Tangible BV |
12.28 | 26.72 | 13.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
5.13 | 4.91 | 3.70 | 5.38 | 4.11 | 3.58 | 3.99 | 3.04 | 3.18 | 2.99 |
EV/EBITDA |
15.83 | 17.23 | 12.64 | 20.95 | 49.85 | 8.84 | 10.23 | 7.51 | 125.67 | 10.81 |
EV/Operating CF |
32.60 | 19.34 | 11.81 | 17.15 | 12.45 | 10.25 | 14.08 | 9.86 | 10.10 | 10.18 |
EV/FCF |
54.10 | 24.17 | 13.65 | 19.09 | 13.15 | 10.90 | 15.40 | 10.80 | 11.01 | 11.22 |
Quick Ratio |
1.35 | 1.37 | 1.36 | 1.26 | 1.28 | 1.20 | 0.87 | 1.04 | 0.91 | 0.94 |
Current Ratio |
1.55 | 1.55 | 1.66 | 1.60 | 1.58 | 1.52 | 1.25 | 1.43 | 1.25 | 1.26 |
Net Debt/EBITDA |
0.06 | 0.19 | (0.21) | 4.66 | 9.93 | 1.47 | 1.67 | 1.51 | 31.77 | 2.58 |
Debt/Assets |
19.90% | 23.73% | 21.01% | 35.96% | 42.77% | 40.76% | 40.61% | 41.80% | 53.61% | 50.10% |
Debt/Equity |
0.41 | 0.67 | 0.52 | 0.90 | 1.34 | 1.24 | 1.26 | 1.35 | 3.03 | 2.44 |
Asset Turnover |
0.59 | 0.62 | 0.66 | 0.32 | 0.34 | 0.41 | 0.45 | 0.47 | 0.51 | 0.53 |
Operating CF/Net income |
0.69 | 5.24 | 1.44 | 2.39 | (1.56) | 2.32 | 2.07 | 1.73 | (1.70) | 2.01 |
Capex/Depreciation |
(3.18) | (1.34) | (1.49) | (0.48) | (0.07) | (0.09) | (0.11) | (0.12) | (0.13) | (0.33) |
| 28.97% | 7.14% | 37.88% | 10.45% | (20.13%) | 18.93% | 18.85% | 26.48% | (39.01%) | 40.43% | |
| 13.62% | 2.99% | 14.36% | 4.17% | (7.26%) | 6.14% | 6.14% | 8.36% | (9.53%) | 7.72% | |
ROIC |
22.13% | 24.67% | 29.33% | 3.74% | (5.90%) | 7.96% | 7.88% | 9.26% | (9.49%) | 11.01% |
Return on Tangible Assets |
45.28% | 9.78% | 40.70% | 19.88% | (53.04%) | 40.10% | 54.37% | 49.68% | (68.09%) | 52.19% |
Average Days of Receivables |
104.14 | 110.68 | 92.98 | 107.29 | 72.98 | 73.72 | 78.17 | 88.57 | 81.21 | 86.44 |
Research and Development Expense of Revenue |
25.80% | 31.13% | 28.07% | 23.52% | 23.63% | 21.98% | 20.60% | 20.66% | 23.10% | 20.65% |
Selling, General and Administrative Expense of Revenue |
25.63% | 22.87% | 20.17% | 18.63% | 18.02% | 16.58% | 16.93% | 17.27% | 17.42% | 15.08% |
Intangible Assets out of Total Assets |
0.25 | 0.24 | 0.22 | 0.67 | 0.62 | 0.58 | 0.59 | 0.51 | 0.49 | 0.45 |
Share Based Compensation of Revenue |
1.06% | 0.96% | 0.98% | 1.69% | 1.83% | 1.26% | 0.99% | 1.15% | 1.05% | 1.15% |
Graham Net Nets |
(0.04) | (0.07) | (0.04) | (0.45) | (0.36) | (0.29) | (0.25) | (0.31) | (0.40) | (0.38) |
Graham Number |
24.24 | 9.94 | 24.29 | 38.83 | 0.00 | 33.90 | 31.30 | 35.27 | 0.00 | 26.61 |
Earnings Yield |
4.49% | 0.99% | 5.83% | 3.44% | (6.45%) | 5.05% | 4.12% | 7.35% | (7.81%) | 6.41% |
Free Cash Flow Yield |
1.86% | 4.18% | 7.20% | 6.74% | 9.49% | 11.00% | 7.76% | 11.59% | 12.16% | 11.71% |
Revenue per Share |
11.63 | 12.63 | 13.82 | 15.33 | 18.83 | 20.88 | 21.67 | 21.75 | 23.83 | 23.69 |
Operating CF per Share |
1.83 | 3.21 | 4.33 | 4.82 | 6.22 | 7.30 | 6.13 | 6.70 | 7.49 | 6.96 |
Capex per Share |
(0.73) | (0.64) | (0.58) | (0.49) | (0.33) | (0.44) | (0.52) | (0.58) | (0.62) | (0.64) |
Free Cash Flow per Share |
1.10 | 2.57 | 3.74 | 4.32 | 5.89 | 6.86 | 5.61 | 6.11 | 6.88 | 6.32 |
Cash per Share |
3.80 | 4.14 | 5.36 | 9.03 | 7.01 | 7.64 | 4.34 | 5.94 | 5.36 | 5.25 |
Shareholders Equity per Share |
9.78 | 7.20 | 8.65 | 30.32 | 16.78 | 16.21 | 14.61 | 14.25 | 8.08 | 9.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.78 | 7.20 | 8.65 | 30.32 | 16.78 | 16.21 | 14.61 | 14.25 | 8.08 | 9.10 |
Free Cash Flow |
1,843.00 | 4,220.00 | 6,115.00 | 7,374.00 | 13,299.00 | 15,234.00 | 11,948.00 | 12,651.00 | 13,942.00 | 12,845.00 |
Working Capital |
4,863.00 | 5,291.00 | 7,062.00 | 11,050.00 | 11,112.00 | 11,394.00 | 5,383.00 | 9,508.00 | 6,006.00 | 5,973.00 |
Capital Expenditures |
(1,215.00) | (1,055.00) | (951.00) | (836.00) | (753.00) | (973.00) | (1,118.00) | (1,209.00) | (1,248.00) | (1,311.00) |
Net Current Asset Value |
(3,656.00) | (6,850.00) | (3,143.00) | (48,892.00) | (50,407.00) | (40,046.00) | (38,429.00) | (33,904.00) | (46,435.00) | (42,142.00) |
EV/EBIT |
16.86 | 19.88 | 13.99 | 28.30 | 0.00 | 20.51 | 23.85 | 16.19 | 0.00 | 15.45 |
Capex to Sales |
0.06 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
Price to Operating Income |
16.79 | 19.66 | 14.22 | 22.00 | 0.00 | 17.10 | 19.96 | 12.93 | 0.00 | 11.76 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.08 | 0.16 | 0.13 | 0.28 | 1.76 | 1.77 | 1.64 | 1.47 | 1.35 | 0.53 |
Cash ROIC |
6.27% | 15.85% | 20.22% | 6.48% | 12.74% | 15.62% | 14.99% | 15.52% | 18.13% | 17.29% |
Accounts Receivable Turnover |
3.95 | 3.51 | 3.75 | 3.89 | 5.25 | 5.19 | 4.79 | 4.33 | 4.46 | 4.35 |
Accounts Payable Turnover |
3.08 | 3.07 | 3.12 | 3.73 | 4.56 | 3.51 | 3.39 | 3.40 | 4.07 | 3.88 |
Inventory Turnover |
4.04 | 5.00 | 5.48 | 2.94 | 3.70 | 4.77 | 4.57 | 4.28 | 5.35 | 5.31 |
Average Days of Payables |
122.23 | 136.44 | 106.79 | 110.48 | 84.11 | 108.29 | 109.46 | 111.24 | 94.12 | 93.63 |
Days of Inventory on Hand |
91.16 | 70.77 | 67.45 | 193.98 | 64.30 | 76.93 | 84.22 | 90.87 | 66.82 | 70.45 |
Average Receivables |
4,921.00 | 5,921.50 | 6,023.50 | 6,716.00 | 8,093.00 | 8,935.00 | 9,627.50 | 10,403.50 | 10,834.00 | 11,080.50 |
Average Payables |
1,614.50 | 1,956.00 | 2,070.00 | 2,168.50 | 2,579.00 | 2,831.00 | 2,994.50 | 3,149.50 | 3,430.50 | 3,588.50 |
Average Inventory |
1,231.00 | 1,203.50 | 1,180.50 | 2,744.00 | 3,183.50 | 2,084.50 | 2,217.00 | 2,500.50 | 2,609.50 | 2,623.50 |
Average Assets |
32,727.50 | 33,629.00 | 34,268.50 | 82,465.00 | 124,212.50 | 113,897.50 | 103,067.00 | 95,989.50 | 93,881.00 | 91,320.50 |
Average Common Equity |
15,385.50 | 14,097.00 | 12,987.00 | 32,912.50 | 44,790.00 | 36,944.00 | 33,562.00 | 30,301.50 | 22,936.50 | 17,447.00 |
Columns are period end dates